[go: up one dir, main page]

WO1995001170A3 - Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders - Google Patents

Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders Download PDF

Info

Publication number
WO1995001170A3
WO1995001170A3 PCT/EP1994/002106 EP9402106W WO9501170A3 WO 1995001170 A3 WO1995001170 A3 WO 1995001170A3 EP 9402106 W EP9402106 W EP 9402106W WO 9501170 A3 WO9501170 A3 WO 9501170A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
gastrointestinal disorders
phenethanolamine derivatives
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1994/002106
Other languages
French (fr)
Other versions
WO1995001170A2 (en
Inventor
Richard Storer
Michael Walter Foxton
Charles David Hartley
Richard Howard Green
Stuart Travers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU73840/94A priority Critical patent/AU7384094A/en
Priority to JP7503267A priority patent/JPH08512038A/en
Priority to EP94923697A priority patent/EP0706386A1/en
Publication of WO1995001170A2 publication Critical patent/WO1995001170A2/en
Anticipated expiration legal-status Critical
Publication of WO1995001170A3 publication Critical patent/WO1995001170A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of compounds of formula (I) in which: R0 is hydrogen, methyl or hydroxymethyl; R1 is substituted alkyl; R?2 and R3¿ are each hydrogen, halogen, hydroxy, alkoxy, carboxy, alkoxycarbonyl, alkyl, nitro, haloalkyl group, or substituted alkyl; X is oxygen or sulphur; and Ar is optionally substituted phenyl or naphtyl; and pharmaceutically acceptable salts thereof in the treatment of gastrointestinal disorders is described.
PCT/EP1994/002106 1993-07-01 1994-06-29 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders Ceased WO1995001170A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU73840/94A AU7384094A (en) 1993-07-01 1994-06-29 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
JP7503267A JPH08512038A (en) 1993-07-01 1994-06-29 Uses of phenethanolamine derivatives for the treatment of gastrointestinal disorders
EP94923697A EP0706386A1 (en) 1993-07-01 1994-06-29 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9313574.7 1993-07-01
GB939313574A GB9313574D0 (en) 1993-07-01 1993-07-01 Medicaments

Publications (2)

Publication Number Publication Date
WO1995001170A2 WO1995001170A2 (en) 1995-01-12
WO1995001170A3 true WO1995001170A3 (en) 2002-02-14

Family

ID=10738090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/002106 Ceased WO1995001170A2 (en) 1993-07-01 1994-06-29 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders

Country Status (5)

Country Link
EP (1) EP0706386A1 (en)
JP (1) JPH08512038A (en)
AU (1) AU7384094A (en)
GB (1) GB9313574D0 (en)
WO (1) WO1995001170A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (en) * 1991-11-20 1996-09-04 Sankyo Co Aromatic amino-alcohol derivatives and intermediates for their preparation
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
DE69711519T2 (en) 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazole analogues as selective beta3-adrenergic agonists
GB9706707D0 (en) * 1997-04-02 1997-05-21 Glaxo Group Ltd Chemical compounds
CO5011072A1 (en) 1997-12-05 2001-02-28 Lilly Co Eli ETANOLAMINAS PIRAZINIL SUBSTITUTED AS AGFONISTS OF THE RECEPTORS
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ES2288543T3 (en) 2001-03-08 2008-01-16 Glaxo Group Limited BETA-ADRENORRECEPTORS AGONISTS.
ES2296923T3 (en) 2001-03-22 2008-05-01 Glaxo Group Limited FORMANILID DERIVATIVES AS AGONISTS OF THE BETA2 ADRENORRECEPTOR.
DK1425001T3 (en) 2001-09-14 2009-04-14 Glaxo Group Ltd Phenethanolamine derivatives for the treatment of respiratory diseases
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0473285A1 (en) * 1990-07-30 1992-03-04 Imperial Chemical Industries Plc Use of 2-(phenoxypropanolamino)ethoxyphenoxyacetic acid and its derivatives to inhibit gastrointestinal motility
EP0516349A2 (en) * 1991-05-28 1992-12-02 Zeneca Limited 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists
EP0543662A2 (en) * 1991-11-20 1993-05-26 Sankyo Company Limited Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
EP0556880A2 (en) * 1992-01-22 1993-08-25 Glaxo Group Limited Medical use for atypical beta-adrenoceptor agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0473285A1 (en) * 1990-07-30 1992-03-04 Imperial Chemical Industries Plc Use of 2-(phenoxypropanolamino)ethoxyphenoxyacetic acid and its derivatives to inhibit gastrointestinal motility
EP0516349A2 (en) * 1991-05-28 1992-12-02 Zeneca Limited 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists
EP0543662A2 (en) * 1991-11-20 1993-05-26 Sankyo Company Limited Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
EP0556880A2 (en) * 1992-01-22 1993-08-25 Glaxo Group Limited Medical use for atypical beta-adrenoceptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
W.J.DUNN III ET AL.: "Structure-Activity Study of beta-Adrenergic Agents Using the SIMCA Method of Pattern Recognition", J.MED.CHEM., vol. 21, no. 9, 1978, pages 922 - 930 *

Also Published As

Publication number Publication date
EP0706386A1 (en) 1996-04-17
GB9313574D0 (en) 1993-08-18
AU7384094A (en) 1995-01-24
WO1995001170A2 (en) 1995-01-12
JPH08512038A (en) 1996-12-17

Similar Documents

Publication Publication Date Title
AU7578894A (en) Methods for inhibiting smooth muscle cell proliferation and restinosis
NO20025821L (en) 2-aminocarbonyl-9H-purine
ES2187473T3 (en) TRIARYLIMIDAZOLES.
WO1995001170A3 (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
NO944911L (en) Non-peptide takykininreseptorantagonister
ATE502932T1 (en) MACROCYCLIC ANALOGAS AND METHODS FOR THE USE AND PRODUCTION THEREOF
HU9600834D0 (en) Quinazoline derivatives
ES2157957T3 (en) PROCEDURES TO INHIBIT ENDOMETRIOSIS.
AU2001272666A1 (en) 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
DK0651999T3 (en) Methods for inhibiting uterine fibrosis
WO1999024022A3 (en) Isoquinoline derivatives for treating disorders associated with 5ht7 receptors
SE9701304D0 (en) Compounds
DK0652002T3 (en) Use of 2-phenyl-3-aroylebenzothiophenes in the manufacture of a drug for inhibiting cartilage degradation
AU635779B2 (en) 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy
WO1999012933A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
SE9803773D0 (en) Compounds
ATE330958T1 (en) PYRAZINO 1'2':1,6ÖPYRIDO 3,4-BÖINDOL DERIVATIVES
EP1121932A4 (en) Remedies for ocular diseases
DE69430074D1 (en) ANALGETIC 4-ARYLISOINDOLS
EP0204003A4 (en) 2- (1-PIPERAZINYL) -4-SUBSTITUTED PHENYLQUINOLINE SCRUBBINGS.
AU5706886A (en) 1,3-oxathiane derivatives
TW429147B (en) Pharmaceutical composition for the treatment of CNS disorders
CA2187402A1 (en) Quinoxaline Derivatives for Treating Tinnitus
EP0811620A4 (en) PHENYLAMIDINOTHIOPHENE DERIVATIVES AND ANTIPHLOGISTIC AGENTS CONTAINING THEM

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994923697

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 564279

Date of ref document: 19960314

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1994923697

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWR Wipo information: refused in national office

Ref document number: 1994923697

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994923697

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG